Antigens Patents (Class 435/69.3)
-
Publication number: 20100062028Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.Type: ApplicationFiled: July 16, 2007Publication date: March 11, 2010Inventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
-
Patent number: 7674892Abstract: The hsp70 gene from an Arthrobacter species has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens.Type: GrantFiled: July 14, 2003Date of Patent: March 9, 2010Assignee: Novartis AGInventors: Steven Gareth Griffiths, Rachael Jane Ritchie, Nathalie C. Simard
-
Publication number: 20100055135Abstract: This invention relates to a HB vaccine enhancing protein, its gene, gene engineering method for expressing this protein, and the application of this method. The cDNA of this protein, which is screened out from human liver cDNA library, is sequenced and then cloned into prokaryotic or eukaryotic (animal or plant) cell for expression of protein coded by the cDNA (for example, cloning into prokaryotic expression carrier and expression in E. coli) and purification of the protein. The protein obtained, when used with HB vaccine, can significantly increase the effect of the vaccine, the immune power of HBV carrier, and the titer of antibody. The protein can be used as an adjutant to HB vaccine.Type: ApplicationFiled: March 16, 2007Publication date: March 4, 2010Applicant: FUDAN UNIVERSITYInventors: Naishuo Zhu, Huaqing Li, Min Yang
-
Patent number: 7666988Abstract: The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: March 7, 2000Date of Patent: February 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Defrenne, Christine Delmelle, Jean-Louis Ruelle
-
Patent number: 7666625Abstract: The present invention relates to methods of producing a heterologous biological substance, comprising: (a) cultivating a mutant of a parent Bacillus cell under conditions conducive for the production of the heterologous biological substance, wherein (i) the mutant cell comprises a first nucleic acid sequence directing synthesis of the heterologous biological substance and a second nucleic acid sequence comprising a modification of at least one of the genes cypX and yvmC, which are involved in the production of a red pigment, and (ii) the mutant cell is deficient in the production of the red pigment compared to the parent Bacillus cell when cultivated under the same conditions; and (b) recovering the heterologous biological substance from the cultivation medium. The present invention also relates to mutants of Bacillus cells and methods for producing the mutants.Type: GrantFiled: December 9, 2008Date of Patent: February 23, 2010Assignee: Novozymes, Inc.Inventors: Maria Tang, Alan Sloma, David Sternberg, Linda Sternberg, legal representative, Regine Behr
-
Patent number: 7666433Abstract: The construction of recombinant respiratory syncytial virus (RSV) strains deleted of the region of G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients is disclosed. Using reverse genetics, recombinant RSV strains were engineered with deletions of amino acids 151-221 and 178-219. Both RSV strains replicated in the respiratory tract of BALB/c mice and elicited serum neutralization and anti-F protein IgG titers that were equivalent to cp-RSV and contributed to a 3.9 log10 reduction in RSV A2 four days after challenge. Importantly, pulmonary eosinophilia was significantly diminished in BALB/c mice primed with native G protein and challenged with either recombinant RSV strain. These findings are important for the development of immunogenic compositions against RSV.Type: GrantFiled: June 29, 2005Date of Patent: February 23, 2010Assignee: Wyeth Holdings CorporationInventors: Gerald E. Hancock, Matthew B. Elliott
-
Patent number: 7662399Abstract: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 12, 2004Date of Patent: February 16, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 7662588Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: November 29, 2006Date of Patent: February 16, 2010Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning
-
Patent number: 7658931Abstract: Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.Type: GrantFiled: December 19, 2007Date of Patent: February 9, 2010Assignees: Wyeth Holdings Corporation, The United States of America, as represented by the Uniformed Services University of Health SciencesInventors: Bruce A. Green, Randall K. Holmes, Michael G. Jobling, Duzhang Zhu
-
Publication number: 20100028375Abstract: An isolated protein comprising a VP1 amino acid sequence wherein one or more exposed loops within said VP1 has an insertion of an amino acid sequence from a virus protein other than VP1, and encoding nucleic acid, are provided. Typically, the virus protein other than VP1 is derived from an influenza virus and in particular, avian influenza virus. The isolated protein may have an insertion of amino acid sequence from a single protein or a plurality of proteins. Also provided are expression constructs, VLPs, pharmaceutical compositions, vaccines and methods of treatment that may be useful in the prophylactic and/or therapeutic treatment of any disease of viral origin, and in particular, influenza virus.Type: ApplicationFiled: October 4, 2007Publication date: February 4, 2010Applicant: The University of QueenslandInventors: Linda Hwee-Lin Lua, Anton Peter Jacob Middelberg
-
Patent number: 7655241Abstract: The present invention concerns the use of methods and compositions to prophylactically or therapeutically vaccinate a subject against a pathogen or disease. Embodiments of the invention include the production of an attenuated bacterium from the family Enterobacteriaceae with a non-functional lipoprotein for use as a vaccine or as a vaccine vector for delivering antigens to a subject to be vaccinated. In certain embodiments, a bacterium of the Enterobacteriaceae family lacking a wild type LP, for example Salmonella typhimurium lacking a wild type LP, may be produced and used as a vaccine or vaccine vector.Type: GrantFiled: March 20, 2003Date of Patent: February 2, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Gary R. Klimpel, David W. Niesel, Ashok Chopra, Jian Sha
-
Publication number: 20100021486Abstract: The invention relates to compositions for the treatment of TH2 mediated inflammatory conditions. The compositions are vaccines comprising a non-primate TSLP or fragments thereof to be used as a vaccine to treat humans with excessive mediated inflammatory conditions. For the treatment of TH2 mediate inflammatory conditions in other non-human mammals the TSLP of the species to be vaccinated is being used as antigen.Type: ApplicationFiled: November 26, 2007Publication date: January 28, 2010Applicant: Theravac Pharmaceuticals ABInventor: Lars Hellman
-
Publication number: 20090324634Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.Type: ApplicationFiled: April 28, 2008Publication date: December 31, 2009Inventors: Elisabeth Knapp, Vidadi Yusibov
-
Publication number: 20090317866Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first polynucleotide comprising a nucleic acid sequence encoding the polypeptide operably linked to a copper-inducible promoter sequence comprising a copper-responsive upstream activation sequence activated by a copper-dependent trans-acting transcription factor and a second polynucleotide comprising one or more (several) additional copper-responsive upstream activation sequences operably linked upstream to the promoter sequence, wherein the promoter sequence is foreign to the nucleic acid sequence encoding the polypeptide and the copper-responsive upstream activation sequences are responsible for copper-induced transcription of the promoter sequence, and a third polynucleotide comprising at least one copy of a gene encoding the copper-dependent trans-acting transcription factor; and (b) isolatType: ApplicationFiled: July 13, 2007Publication date: December 24, 2009Applicants: Novozymes, Inc., Novozymes A/SInventors: Barbara Cherry, Debbie Yaver, Mads Bjornvad
-
Patent number: 7632511Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: December 31, 2006Date of Patent: December 15, 2009Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Publication number: 20090304727Abstract: The present invention relates to recombinant DNA molecules which encode chimeric polypeptides of differing allergens of Parietaria judaica which can be used for the prevention and treatment of allergies, in particular pollen allergies. Specifically, chimeric polypeptides composed of fragments of the allergens Par j 1 and Par j 2 having hypoallergenic characteristics are described. Methods for producing these recombinant polypeptides in heterologous expression systems are also described. Efficient methods of purifying the chimeric proteins are also described.Type: ApplicationFiled: April 11, 2007Publication date: December 10, 2009Applicant: BIAL INDUSTRIAL FARMACEUTICA, S.A.Inventors: Juan Andres Asturias Ortega, Alberto Martinez Garate, Roberto Gonzales Rioja
-
Publication number: 20090297550Abstract: Disclosed is a method of making a malaria vaccine, the method comprising stably transforming a plant by inserting into its plastid genome a nucleic acid sequence encoding and operable to constitutively express a malaria antigenic polypeptide selected from AMA-1, MSP-1 or both; harvesting the stably transformed plant in whole or in part; purifying the expressed malaria antigenic polypeptide from the harvested plant; and packaging the purified antigenic polypeptide under sterile conditions in an amount for a predetermined dosage. Also disclosed is an oral vaccine effective in raising malaria antibodies in a susceptible host, the vaccine comprising leaf material from an edible plant containing plastids stably transformed to constitutively express a fusion polypeptide consisting essentially of cholera toxin B subunit and a malaria antigenic polypeptide selected from AMA-1, MSP-1 or both.Type: ApplicationFiled: October 31, 2008Publication date: December 3, 2009Inventors: Henry Daniell, Debopam Chakrabarti
-
Patent number: 7626000Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: December 20, 2006Date of Patent: December 1, 2009Assignee: Sanofi Pasteur Limited/Sanofi Pasteur LimitéeInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Patent number: 7625569Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: December 31, 2006Date of Patent: December 1, 2009Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Publication number: 20090285821Abstract: The present disclosure provides coding and amino acid sequences for a Campylobacter jejuni pilus protein (and from other species as well). This protein, when administered to a human or animal, elicits the expression of an immune response to Campylobacter jejuni, with the result that colonization and/or infection by this organism is reduced. Recombinant protein or biofilm material comprising the pilus protein is formulated into immunogenic compositions, especially for mucosal administration. Thus, the present invention provides methods for improvement of the microbial quality of food products including poultry, eggs, meat and dairy products, and indirectly of plant foods that may come in contact with agricultural waste, either from fertilization or from irrigation water.Type: ApplicationFiled: December 1, 2006Publication date: November 19, 2009Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Lynn Joens, James R. Theoret, Ryan J. Reeser, Bibiana Law
-
Publication number: 20090288178Abstract: A transgenic insect cell line for production of recombinant glycoproteins possessing sulfated, complex N-glycans is provided.Type: ApplicationFiled: April 10, 2009Publication date: November 19, 2009Inventor: Donald L. Jarvis
-
Publication number: 20090280168Abstract: The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polypeptides relate to the 98 KDa OMP antigen designated CPN100686 RY 54 (SEQ ID No:14, encoded in one form by SEQ ID NO:1).Type: ApplicationFiled: May 26, 2009Publication date: November 12, 2009Applicant: SANOFI PASTEUR LIMITEDInventors: ANDREW D. MURDIN, RAYMOND P. OOMEN, JOE WANG
-
Publication number: 20090280125Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: ApplicationFiled: April 23, 2009Publication date: November 12, 2009Inventors: Scott Napper, Peter Hedlin, Philip Griebel, Lorne Babiuk, Neil Cashman, Avijit Chakrabartty, Andrew Potter
-
Patent number: 7615228Abstract: A purified polypeptide comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of a polymer with n monomeric polypeptides, wherein n is an integer from 2-180; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: September 30, 2001Date of Patent: November 10, 2009Assignee: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Patent number: 7611866Abstract: The invention overcomes the deficiencies of the prior art by providing a rapid approach for isolating polypeptides capable of anchoring heterologous polypeptides to a bacterial inner membrane. In the technique, libraries of candidate anchor polypeptides are expressed as fusions with a heterologous polypeptide that is capable of being detected when bound to the inner membrane. In bacteria expressing a functional anchor sequence, the heterologous polypeptide becomes bound to outer face of the inner membrane. Bacteria with the functional anchor sequence can be identified by removing the outer membrane to remove non-anchored heterologous polypeptide followed by detection of anchored heterologous polypeptide. Such bacteria may be detected in numerous ways, including use of direct fluorescence or secondary antibodies that are fluorescently labeled, allowing use of efficient techniques such as fluorescence activated cell sorting (FACS).Type: GrantFiled: March 18, 2005Date of Patent: November 3, 2009Assignee: Board of Regents, The University of Texas SystemInventors: George Georgiou, Ki Jun Jeong, Barrett R. Harvey, Brent L. Iverson
-
Patent number: 7604961Abstract: A pure, water-soluble polypeptide containing one or more monomers of a VP1 protein of a foot-and-mouth disease virus; or a pure, water-insoluble polypeptide comprising two or more monomers of a VP1 protein of a foot-and-mouth disease virus. Also disclosed are a vaccine containing the polypeptide, a method of producing the polypeptide, and a method of inducing an immune response in a subject by administering to the subject an effective amount of the polypeptide.Type: GrantFiled: May 14, 2007Date of Patent: October 20, 2009Assignee: Academia SinicaInventors: Shu-Mei Liang, Jeng-Hwan Wang, Jeng-Jer Shieh
-
Publication number: 20090246228Abstract: Novel antigens of B. catarrhalis are provided, together with their use in vaccines as well as methods of diagnosing and/or detection.Type: ApplicationFiled: June 8, 2009Publication date: October 1, 2009Inventors: Allan William CRIPPS, Jennelle Kyd
-
Publication number: 20090246830Abstract: A method for producing influenza virus particles for preparation of a vaccine. The method comprises growing reassortant influenza viruses to produce virus particles and recovering the produced virus particles. The reassortant influenza viruses are produced in cultured cells in the absence of helper virus by introducing into the cultured cells expression vectors sufficient to produce genomic vRNA or antigenomic vRNA (cRNA) segments in the cells of reassortant influenza viruses. The method produces a nucleoprotein and an RNA dependent RNA polymerase in the cells so that RNP complexes containing the genomic vRNA segments of the reassortant influenza viruses are formed. The method uses expression vectors containing HA, NA, non-HA and non-NA vRNA segments in which the HA and NA vRNA segments are HA and NA vRNA segments of a viral strain different from a strain that contains all of the non-HA and non-NA vRNA segments.Type: ApplicationFiled: January 7, 2009Publication date: October 1, 2009Applicant: Wisconsin Alumni Research FoundationInventors: Yoshihiro KAWAOKA, Gabriele Neumann
-
Patent number: 7595191Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: January 24, 2005Date of Patent: September 29, 2009Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jeffrey A. Lyon, Evelina Angov
-
Patent number: 7595059Abstract: Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.Type: GrantFiled: August 21, 2006Date of Patent: September 29, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Victor C. W. Tsang, Ryan M. Greene, Patricia P. Wilkins, Kathy Hancock
-
Publication number: 20090238822Abstract: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.Type: ApplicationFiled: October 13, 2006Publication date: September 24, 2009Applicant: VIREXX MEDICAL CORP.Inventors: Rajan George, Lorne Tyrrell, Antoine A. Noujaim, Bruce Darryl Hirsche, Dakun Wang, Allan Ma, Bruce Motyka
-
Publication number: 20090238841Abstract: Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject.Type: ApplicationFiled: February 2, 2009Publication date: September 24, 2009Inventors: John Donnelly, Susan W. Barnett, Derek O'Hagan
-
Publication number: 20090239261Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.Type: ApplicationFiled: June 2, 2009Publication date: September 24, 2009Applicant: WYETH HOLDINGS CORPORATIONInventors: JOSE M. GALARZA, THERESA E. LATHAM
-
Publication number: 20090226485Abstract: This invention relates to a recombinant vector including a recombinant porcine adenovirus, stably incorporating and capable of expression of at least one heterologous nucleotide sequence. The nucleotide sequence is preferably one which encodes an antigenic determinant of Hog Cholera Virus or Pseudorabies virus. The further invention relates to a method of production of recombinant vectors, to methods of preparation of vaccines based on the vectors, to administration strategies and to methods of protecting pigs from disease.Type: ApplicationFiled: August 22, 2008Publication date: September 10, 2009Applicants: Commonwealth Scientific and Industrial Research Organisation, Pig Research Development CorporationInventors: Michael A. Johnson, Jeffrey Michael Hammond, Richard J. McCoy, Michael G. Sheppard
-
Publication number: 20090220538Abstract: The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology.Type: ApplicationFiled: July 13, 2006Publication date: September 3, 2009Applicant: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Murthy Ella, Kandaswamy Sumathy, Krishna Mohan Vadrevu
-
Patent number: 7582731Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: December 20, 2006Date of Patent: September 1, 2009Assignee: Sanofi Pasteur LimitedInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Patent number: 7582449Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: May 11, 2007Date of Patent: September 1, 2009Assignees: Sanofi Pasteur Limited, Sanofi Pasteur LimitéeInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Publication number: 20090215146Abstract: The invention relates to a method for producing virus-type particles containing an active substance. Proteins, which comprise a first amino acid sequence which is derived from a first virus protein, and fusion proteins are assembled in order to form the virus-type particles. The proteins and the fusion proteins are coexpressed in yeast cells.Type: ApplicationFiled: March 28, 2006Publication date: August 27, 2009Applicant: responsif GmbHInventors: Christoph Reichel, Claus Rühland, Jurgen Hess, Cristian Reiser
-
Publication number: 20090214570Abstract: The present invention relates, in part, to methods and compositions for immunizing against infection by Chlamydia trachomatis. The methods and compositions rely, in part, on administering an immunogenic composition comprising one or more peptides derived from C. trachomatis major outer membrane protein (MOMP) to a subject to be immunized. In some embodiments, the compositions comprise a chimeric immunogen comprising a receptor binding domain, a translocation domain, and a Chlamydia trachomatis antigen. Polynucleotides encoding the chimeric immunogens, expression vectors comprising the polynucleotides, and kits comprising the compositions are also provided.Type: ApplicationFiled: May 17, 2006Publication date: August 27, 2009Applicants: Trinity Biosystems, Inc., Children's Hospital & Research Center at OaklandInventors: Randall J. Mrsny, Deborah Dean
-
Publication number: 20090214579Abstract: It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.Type: ApplicationFiled: August 21, 2008Publication date: August 27, 2009Inventors: Masaya Takemoto, Yasuko Mori, Koichi Yamanishi, Isao Fuke, Yasuyuki Gomi, Michiaki Takahashi
-
Patent number: 7579007Abstract: This application provides a method to form non-infectious Biological Carrier that may be used to deliver signals to cells either in vitro or in vivo. The Biological Carriers are inactivated virus particles that have been specifically modified to give biological properties different from the virus particles deriving from an unmodified host cell that (i) expresses at least one co-stimulatory molecule and (iia) at least one antigen that can initiate an immune response, and/or (iib) express surface molecules that suppress viral replication.Type: GrantFiled: February 12, 2002Date of Patent: August 25, 2009Assignee: JDM Technologies, Inc.Inventor: Joseph D. Mosca
-
Publication number: 20090208978Abstract: A panel cell for detecting anti-HNA antibody is disclosed. The panel cell is obtained by introducing a DNA coding for an HNA antigen corresponding to the anti-HNA antibody into a cell so as to enable the expression of the DNA under the condition for use in the detection procedure, wherein the cell for DNA introduction exhibits no detectable reaction with anti-HLA-ABC antibody, anti-HLA-DR antibody, anti-HLA-DQ antibody, anti-HLA-DP antibody, anti-HNA-1 antibody, anti-HNA-2a antibody, anti-HNA-3a antibody, anti-HNA-4 antibody, anti-HNA-5 antibody, and serum from normal subject, in the detection procedure. The panel cell allows accurate and rapid detection of granulocyte antibody.Type: ApplicationFiled: March 13, 2007Publication date: August 20, 2009Inventors: Kazuta Yasui, Fumiya Hirayama, Rika Furuta, Nobuki Matsuyama, Yoshitaka Kojima, Toru Miyazaki, Hisami Ikeda, Yoshihisa Watanabe
-
Publication number: 20090209003Abstract: The present invention is to construct a DNA replication reaction system which is excellent in versatility and is easily used. An amino acid sequence of a PCNA monomer which is one of factors involved in DNA replication is prepared so that amino acid residues causing mutual charge repulsion constitute a site which causes, when an N terminal region of the PCNA monomer and a C terminal region of another PCNA monomer act as an interface to form a multimeric complex, an intermolecular interaction of the monomers in an interface region of the monomers.Type: ApplicationFiled: July 4, 2006Publication date: August 20, 2009Inventors: Tadaaki Tokida, Satoshi Hihara, Takashi Kudou, Akira Kawamura, Hirofumi Doi, Yoshizumi Ishino
-
Publication number: 20090196884Abstract: The present invention relates to a synthetic antigenic sequence which represents a combination of epitope-containing sequences from the highly polymorphic block 2 repeat region of K1-type Plasmodium falciparum merozite surface antigen (MSP1) and fusion proteins containing that sequence in combination with additional epitope-containing sequences capable of inducing antibody and cellular immune responses to P.Type: ApplicationFiled: May 26, 2006Publication date: August 6, 2009Applicant: LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINEInventors: Kevin K. Tetteh, David J. Conway
-
Publication number: 20090197304Abstract: The present invention provides a system for site-specific directed gene insertion of desired genes or foreign DNA into cellular genomes. The system includes novel vectors for integrating DNA into the genome of different hosts. Methods of using the vectors and transformed hosts are described.Type: ApplicationFiled: September 14, 2007Publication date: August 6, 2009Inventors: Diana M. Oram, Mark Oram, Joelle Woolston
-
Publication number: 20090196883Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: ApplicationFiled: January 18, 2006Publication date: August 6, 2009Inventors: Anjali Yadava, Christian F. Ockenhouse
-
Patent number: 7569666Abstract: The invention concerns novel means for diagnosing, preventing, compensating, treating an abnormal or unwanted functioning of KAR receptors (Killer cell Activatory Receptor), counterparts of non-inhibiting KIR receptors (Keller cell Inhibitory Receptors) of the immunoglobulin or lectin type. The invention concerns in particular, novel KARAP (KAR-Associated Proteins) polypeptides and their biological applications. A KARAP polypeptide is naturally associated with a KAR receptor, and in the absence of such a KARAP, said KAR receptor is naturally incapable of transducing an activating signal that can be detected. The application also concerns methods for obtaining or identifying such KARAP polypeptides.Type: GrantFiled: August 2, 2004Date of Patent: August 4, 2009Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Eric Vivier, Alessandro Moretta, Lucia Olcese, Frédéric Vely, Elena Tomasello
-
Publication number: 20090186337Abstract: The invention relates to N protein-protein of interest fusion proteins, optionally in the form of soluble N protein-protein of interest/P protein complexes, the N and P proteins being proteins of a virus of the Paramyxoviridae family. When the protein of interest is an antigen, the invention relates also to vaccinal compositions and diagnostic reagents comprising those N protein-antigen fusion proteins or those N protein-antigen/P protein complexes. The N protein-protein of interest fusion protein can also be used as a “vector” for transporting into cells therapeutic molecules of interest, such as antivirals or anticancer agents.Type: ApplicationFiled: April 18, 2007Publication date: July 23, 2009Inventors: Jean-Francois Eleouet, Sabine Riffault
-
Patent number: 7556940Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.Type: GrantFiled: March 28, 2005Date of Patent: July 7, 2009Assignee: Wyeth Holdings CorporationInventors: Jose M. Galarza, Theresa E. Latham
-
Publication number: 20090170162Abstract: The embodiments described herein provide for immunogenic portions of Streptococcus pneumoniae surface protein A and surface protein C lacking alpha helical structure.Type: ApplicationFiled: February 1, 2007Publication date: July 2, 2009Applicant: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATIONInventors: Susan K. Hollingshead, David E. Briles